

Elemental Nutrition in Gastrointestinal symptom management during pelvic radiotherapy (enigma)

Submission date 30/09/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 30/09/2005	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 10/09/2012	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Jervoise Andreyev

Contact details

Medicine Section
Royal Marsden NHS Trust
Downs Road
Sutton, Surrey
United Kingdom
SM2 5PT
+44 (0)20 8643 8901

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0258152650

Study information

Scientific Title

Acronym

ENiGMa

Study objectives

To identify in patients having pelvic radiotherapy if elemental diet given for 3 weeks can reduce bowel symptoms and change other indicators of these symptoms.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised open label controlled parallel group trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Not Specified

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Pelvic cancers

Interventions

Randomised test intervention versus no intervention controls, non-blinded Phase III

Intervention Type

Other

Phase

Phase III

Primary outcome measure

To assess bowel toxicity using IBDQ and to assess whether there are differences in the score in patients in their intervention arm and the control.

Secondary outcome measures

Not provided at time of registration

Overall study start date

25/11/2004

Completion date

31/07/2006

Eligibility

Key inclusion criteria

102 RMH patients, with a diagnosis of gynaecological or urological malignancy. Will be undergoing a course of radical or adjuvant pelvic radiotherapy to a curative dose (including patients undergoing concomitant chemotherapy).

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

102

Key exclusion criteria

1. Patients with condition precluding oral nutrition
2. Patients undergoing conformal radiotherapy or intra-cavity brachytherapy
3. Patients with clotting disorders

Date of first enrolment

25/11/2004

Date of final enrolment

31/07/2006

Locations

Countries of recruitment

England

United Kingdom

Study participating centre
Medicine Section
Sutton, Surrey
United Kingdom
SM2 5PT

Sponsor information

Organisation
Department of Health

Sponsor details
Richmond House
79 Whitehall
London
United Kingdom
SW1A 2NL
+44 (0)20 7307 2622
dhmail@doh.gsi.org.uk

Sponsor type
Government

Website
<http://www.dh.gov.uk/Home/fs/en>

Funder(s)

Funder type
Government

Funder Name
The Royal Marsden NHS Foundation Trust (UK)

Funder Name
NHS R&D Support Funding

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/06/2008		Yes	No